T 
Takeda Pharmaceutical Co 4502.T · JPY
Health Care · Pharmaceuticals · Tokyo Stock Exchange · 🇯🇵 Japan
6,673
+1.72%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in JPY, from our data supplier.
Revenue
¥4.51trn
FY2017FY2026
Net income
¥191.76bn
FY2017FY2026
Free cash flow
¥762.71bn
FY2017FY2026
Shareholders' equity
¥7.77trn
FY2017FY2026
Income statement
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ¥4.51trn | ¥4.58trn | ¥4.26trn | ¥4.03trn | ¥3.57trn | ¥3.20trn | ¥3.29trn | ¥2.10trn | ¥1.77trn | ¥1.73trn |
| Gross profit | ¥2.30trn | ¥2.46trn | ¥2.32trn | ¥2.30trn | ¥2.04trn | ¥1.80trn | ¥1.79trn | ¥1.28trn | ¥1.15trn | ¥1.02trn |
| Research and development | ¥675.92bn | ¥730.23bn | ¥728.62bn | ¥633.33bn | ¥526.09bn | ¥455.76bn | ¥492.09bn | ¥368.26bn | ¥325.44bn | ¥311.63bn |
| Operating income | ¥540.45bn | ¥627.54bn | ¥531.42bn | ¥658.29bn | ¥610.50bn | ¥447.61bn | ¥302.61bn | ¥218.69bn | ¥195.32bn | ¥86.97bn |
| Net income | ¥191.76bn | ¥107.93bn | ¥144.07bn | ¥317.02bn | ¥230.06bn | ¥376.00bn | ¥44.24bn | ¥135.19bn | ¥186.89bn | ¥114.94bn |
| Diluted earnings per share | 122.72 | 67.35 | 88.30 | 200.00 | 146.50 | 238.75 | 28.07 | 86.79 | 237.03 | 146.16 |
Balance sheet
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | ¥15.45trn | ¥14.25trn | ¥15.11trn | ¥13.96trn | ¥13.18trn | ¥12.91trn | ¥12.82trn | ¥13.87trn | ¥4.11trn | ¥4.36trn |
| Cash and short-term investments | ¥595.05bn | ¥385.11bn | ¥457.80bn | ¥533.53bn | ¥849.70bn | ¥966.22bn | ¥637.61bn | ¥702.09bn | ¥375.17bn | ¥376.14bn |
| Total liabilities | ¥7.68trn | ¥7.31trn | ¥7.83trn | ¥7.60trn | ¥7.49trn | ¥7.74trn | ¥8.09trn | ¥8.61trn | ¥2.09trn | ¥2.40trn |
| Debt | — | ¥4.52trn | ¥4.84trn | ¥4.38trn | ¥4.35trn | ¥4.64trn | ¥5.09trn | ¥5.75trn | ¥985.66bn | ¥1.14trn |
| Shareholders' equity | ¥7.77trn | ¥6.94trn | ¥7.27trn | ¥6.35trn | ¥5.68trn | ¥5.17trn | ¥4.72trn | ¥5.16trn | ¥2.00trn | ¥1.89trn |
| Shares outstanding | 1,563m | 1,602m | 1,632m | 1,585m | 1,570m | 1,575m | 1,576m | 1,558m | 788m | 786m |
Cash flow
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | ¥938.71bn | ¥962.49bn | ¥640.32bn | ¥977.16bn | ¥1.12trn | ¥1.01trn | ¥669.75bn | ¥302.61bn | ¥379.60bn | ¥260.07bn |
| Capital spending | −¥176.00bn | −¥200.79bn | −¥175.42bn | −¥633.69bn | −¥186.04bn | −¥236.47bn | −¥217.71bn | −¥77.68bn | −¥67.00bn | −¥61.66bn |
| Free cash flow | ¥762.71bn | ¥761.70bn | ¥464.90bn | ¥343.47bn | ¥937.07bn | ¥774.46bn | ¥452.04bn | ¥224.93bn | ¥312.60bn | ¥198.41bn |
| Dividends paid | −¥311.90bn | −¥302.50bn | −¥287.19bn | −¥279.42bn | −¥283.67bn | −¥283.36bn | −¥282.58bn | −¥142.95bn | −¥141.89bn | −¥141.69bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ¥1.22trn | ¥1.09trn | ¥1.19trn | ¥1.11trn | ¥1.11trn | ¥1.05trn | ¥1.14trn | ¥1.18trn |
| Gross profit | ¥813.22bn | ¥534.00bn | ¥790.55bn | ¥732.74bn | ¥590.37bn | ¥542.35bn | ¥592.34bn | ¥639.31bn |
| Operating income | ¥201.42bn | ¥46.68bn | ¥168.82bn | ¥69.00bn | ¥190.60bn | ¥30.48bn | ¥59.95bn | ¥195.47bn |
| Net income | ¥113.20bn | −¥24.32bn | ¥103.64bn | −¥11.80bn | ¥124.24bn | −¥103.16bn | ¥23.79bn | ¥92.05bn |
| Diluted earnings per share | 72.44 | -15.56 | 64.68 | -7.36 | 77.53 | -64.37 | 14.58 | 56.41 |
| Cash from operations | ¥127.62bn | ¥40.37bn | ¥348.68bn | ¥378.23bn | ¥203.83bn | ¥191.65bn | ¥352.47bn | ¥259.00bn |
| Capital spending | −¥53.81bn | −¥46.36bn | −¥41.63bn | −¥52.83bn | −¥47.91bn | −¥48.79bn | −¥45.09bn | −¥49.47bn |
| Free cash flow | ¥73.81bn | −¥6.00bn | ¥307.05bn | ¥325.40bn | ¥155.92bn | ¥142.85bn | ¥307.38bn | ¥209.53bn |
| Total assets | ¥15.66trn | ¥15.45trn | ¥15.41trn | ¥14.47trn | ¥14.00trn | ¥14.25trn | ¥15.11trn | ¥14.57trn |
| Cash and short-term investments | ¥527.58bn | ¥595.05bn | ¥761.94bn | ¥739.68bn | ¥350.01bn | ¥385.11bn | ¥494.13bn | ¥859.01bn |
| Debt | ¥4.94trn | ¥4.88trn | ¥4.85trn | ¥4.65trn | ¥4.51trn | ¥4.58trn | ¥4.84trn | ¥5.05trn |
| Shareholders' equity | ¥7.56trn | ¥7.77trn | ¥7.64trn | ¥7.13trn | ¥6.87trn | ¥6.94trn | ¥7.42trn | ¥6.92trn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 3.8% | 7.1% | 9.6% |
| Operating income | -6.4% | 3.8% | 11.9% |
| Net income | -15.4% | -12.6% | 9.1% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 52.3% | 54.0% | 54.8% | 56.3% |
| Operating margin | 12.9% | 13.6% | 14.1% | 12.6% |
| Net margin | 3.3% | 4.4% | 5.7% | 5.5% |
Valuation history
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 53.5 | 71.8 | 47.4 | 20.3 | 28.1 | 13.1 | 133.8 | 49.9 | 15.6 | 43.8 |
| Price to sales | 2.3 | 1.7 | 1.6 | 1.6 | 1.8 | 1.5 | 1.8 | 3.2 | 1.6 | 2.9 |
Dividends and splits
Per share, in the currency the company pays
Paid for 36 years. Last went ex-dividend on 29 Sept 2026.
| FY2027 | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 102.00 | 298.00 | 192.00 | 184.00 | 180.00 | 180.00 | 180.00 | 180.00 |
- 1-to-1 reverse split · 11 Aug 2006
- 1-to-1 reverse split · 9 Aug 2006
- 1-to-1 reverse split · 23 Jun 2006
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.